Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 27.2 1.87% 0.50
ACOR closed up 1.87 percent on Friday, October 20, 2017, on 74 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Oct 31

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ACOR trend table...

Date Alert Name Type % Chg
Oct 20 Spinning Top Other 0.00%
Oct 19 Slingshot Bullish Bullish Swing Setup 1.87%
Oct 17 Stochastic Reached Overbought Other 2.06%
Oct 16 Doji - Bearish? Reversal 4.41%
Oct 12 New Uptrend Bullish 6.67%

Older signals for ACOR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 13.6
Average Volume 831,556
200-Day Moving Average 21.2053
50-Day Moving Average 23.679
20-Day Moving Average 25.465
10-Day Moving Average 26.125
Average True Range 1.0212
ADX 31.09
+DI 32.24
-DI 12.1
Chandelier Exit (Long, 3 ATRs ) 24.5364
Chandelier Exit (Short, 3 ATRs ) 25.7636
Upper Bollinger Band 27.8911
Lower Bollinger Band 23.0389
Percent B (%b) 0.86
BandWidth 19.054388
MACD Line 0.9528
MACD Signal Line 0.8751
MACD Histogram 0.0777
Fundamentals Value
Market Cap 1.27 Billion
Num Shares 46.7 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -28.94
Price-to-Sales 2.32
Price-to-Book 1.80
PEG Ratio 0.54
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.85
Resistance 3 (R3) 28.80 28.20 28.58
Resistance 2 (R2) 28.20 27.78 28.23 28.48
Resistance 1 (R1) 27.70 27.52 27.95 27.75 28.39
Pivot Point 27.10 27.10 27.23 27.13 27.10
Support 1 (S1) 26.60 26.68 26.85 26.65 26.01
Support 2 (S2) 26.00 26.42 26.03 25.92
Support 3 (S3) 25.50 26.00 25.83
Support 4 (S4) 25.55